



IJPPR

INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals

ISSN 2349-7203





Human Journals

Review Article

January 2022 Vol.:23, Issue:2

© All rights are reserved by B. Vinay kumar et al.

Niosomes

 IJPPR INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH An official Publication of Human Journals		ISSN 2349-7203 
<p>B. Vinay kumar*, G.Mounika , P.Nandhini reddy , P.Shruthi.,B.V.P.Deepthi</p> <p><i>Joginapally B R Pharmacy college, Yenkapally, Moinabad, Hyderabad, Telangana. India.</i></p> <p>Submitted: 21 December 2021 Accepted: 26 December 2021 Published: 30 January 2022</p>		



HUMAN JOURNALS

www.ijppr.humanjournals.com

Keywords: Niosome, Cholesterol, Hydrophilic, and Lipophilic drugs, Surfactant, Targeted delivery Bioavailability Improvement, Factors, Applications

ABSTRACT

Niosomes are non-ionic surfactant vesicles obtained on the hydration of synthetic nonionic surfactants, with or without incorporation of cholesterol or their lipids. They are vesicular systems similar to liposomes that can be used as carriers of amphiphilic and lipophilic drugs. Niosomes are promising vehicles for drug delivery and being non-ionic and Niosomes are biodegradable, biocompatible nonimmunogenic, and exhibit flexibility in their structural characterization. Niosomes have been widely evaluated for controlled release and targeted delivery for the treatment of cancer, viral infections, and other microbial diseases. Niosomes can entrap both hydrophilic and lipophilic drugs and can prolong the circulation of the entrapped drug in the body. Encapsulation of the drug in the vesicular system can be predicted to prolong the existence of the drug in the systemic circulation and enhance penetration into the target tissue, perhaps reducing toxicity if selective uptake can be achieved. This review article focuses on the advantages, Disadvantages, preparation methods, factors affecting, characterizations, in-vitro methods, drug release kinetics, and applications of niosome.

INTRODUCTION

The momentum innovative work approach depends on creating drug conveyance frameworks that make clinically demonstrated medications play out their best in treatment as opposed to looking for new medications. The objective of any medication conveyance framework ought to forever be to accomplish the most elevated restorative activity with negligible incidental effects. Non-ionic surfactants can shape vesicular movement, like phospholipids, and when dispersed in water, called niosomes. These vesicles are made by oneself social occasion of hydrated surfactant monomers. Diverged from liposomes, niosomes vanquishes the adequacy-related issues, which fuses oxidation, high economy, and ethicalness that affects size and shape. Both hydrophilic and lipophilic prescriptions can be snared in niosomes. Thus, prescriptions can be passed on generally close by other required materials using niosomes. Recently, these were comprehensively perused up for their changed capacity of the biodistribution and development profile of the prescription. It goes probably as a carrier in the appearance of medicaments, synthetics, antigens, and bioactive particles. Moreover, niosome also goes probably as a substitute variation to loosen up the issue of insolubility, shakiness, and speedy difficulty of drugs.

STRUCTURE OF NIOSOMES




Figure No. 1: Structure of Niosomes

DEFINITION:

A niosome is a non-ionic surfactant-based liposome. Niosomes are shaped for the most part by cholesterol consolidation as an excipient. Other excipients can likewise be utilized. Niosomes have more infiltrating capacity than the past arrangements of emulsions. They are primarily like liposomes in having a bilayer, notwithstanding, the materials used to plan

niosomes make them more steady, and accordingly niosomes offer a lot more benefits over liposomes.

ADVANTAGES OF NIOSOMES

1. The use of niosomes in beauty care products was first finished by L'Oreal as they offered the accompanying benefits.
2. The vesicle suspension being water-based offers more prominent patient consistency over oil-based frameworks.
3. Since the design of the niosome offers a spot to oblige hydrophilic, lipophilic just as amphiphilic drug moieties, they can be utilized for an assortment of medications.
4. The attributes, for example, size, lamellarity, and so on of the vesicle can be changed relying upon the prerequisite.
5. The vesicles can go similarly to a terminal to convey the medicine step by step and proposition a controlled conveyance.

DISADVANTAGES OF NIOSOMES

1. Physical instability
2. Aggregation
3. Fusion
4. Leaking of the entrapped drug
5. Hydrolysis of epitomized drugs restricts the period of usability of the scattering.

PREPARATION METHODS OF NIOSOMES:

The course of action procedures should be picked by the usage of the niosomes since the arranging techniques sway the number of bilayers, size, size dispersal, and catch viability of the watery stage and the layer vulnerability of the vesicles.

A. Ether injection method:

This strategy gives a technique for making niosomes by relaxed introducing a reply of surfactant broke down in diethyl ether into warm water stayed aware of at 60°C. The

surfactant blend in ether is implanted through a 14-register needle with a watery game plan of material.

Preparation steps

Surfactant is dissolved in diethyl ether



Then, at that point, infused in warm water kept up with at 60o C through a 14 dressing needle



Ether is vaporized to form single-layered niosomes.

B. Handshaking method (thin film hydration technique):

The combination of vesicle framing fixings like surfactant and cholesterol are broken up in an unstable natural dissolvable (diethyl ether, chloroform, or methanol) in a round base cup. The natural dissolvable is eliminated at room temperature (20°C) utilizing a turning evaporator leaving a flimsy layer of strong blend kept on the mass of the cup. These cycle structures run of the mill multilamellar niosomes.

Preparation steps

Surfactant + cholesterol + solvent



Remove organic solvent at Room temperature



The thin layer formed on the Walls of the flask



The film can be rehydrated to form multilamellar Niosomes.

C. Sonication Method:

A normal strategy for the creation of the vesicles is by sonication of arrangement as depicted by Cable. In this strategy, an aliquot of medication arrangement in a cradle is added to the surfactant/cholesterol combination in a 10-ml glass vial.

Preparation steps

Drug in cradle + surfactant/cholesterol in 10 ml



The above blend is sonicated for 3 mins at 60°C utilizing titanium test yielding niosomes.

D. Micro fluidization Method:

Miniature fluidization is a new procedure used to get ready unilamellar vesicles of characterized size dissemination. This technique depends on lowered flow standards in which two fluidized streams associate at ultra-high speeds, in exactly characterized miniature channels inside the communication chamber. The impingement of dainty fluid sheet along a typical front is organized to such an extent that the energy provided to the framework stays inside the space of niosomes arrangement. The result is a more unmistakable consistency, more humble size and better reproducibility of niosomes formed.

Preparation steps:

Two ultra-high-speed jets inside the interaction chamber



Formation of uniform Niosomes.

E. Multiple membrane extrusion methods:

A mix of surfactant, cholesterol and diacetyl phosphate in chloroform is made into a humble film by vanishing. The film is hydrated with fluid medication polycarbonate layers, arrangement and the resultant suspension expelled through which are put in series for up to 8 sections. It is a decent strategy for controlling baneful size.

F. Reverse Phase Evaporation Technique (REV):

Cholesterol and surfactant are isolated in a blend of ether and chloroform. A watery stage containing drug is added to this and the following two stages are sonicated at 4-5°C. The indisputable gel outlined is further sonicated later the extension of a restricted amount of phosphate supported saline (PBS). The natural stage is taken out at 40°C under low tension. The subsequent gooey baneful suspension is weakened with PBS and warmed on a water shower at 60°C for 10 min to yield niosomes.

Preparation steps:

Cholesterol + surfactant dissolved in ether + chloroform



Sonicated at 5°C and again sonicated in the wake of adding PBS



The drug in the watery stage is added to the above blend.



Viscous niosomes suspension is diluted with PBS.



The natural stage is taken out at 40°C at low strain.



Warmed on a water shower for 60°C for 10 mins to yield niosomes.

G. TransMembranes PH Gradient (Inside Acidic):

Drug Uptake Process: or Remote Loading Technique Surfactant and cholesterol are broken down in chloroform. The dissolvable is then dissipated under diminished strain to get a slight film on the mass of the round base flagon. The firm is hydrated with 300mM citrus extract (PH 4.00 by vertex blending. A watery arrangement containing 10 mg ml of medication is added and vortexes. The PH of the example is then raised to 1M disodium phosphate. This combination is subsequently warmed at 60°C for 10 minutes so give niosomes.

neck. Cholesterol and surfactant are scattered together in this cushion (PH 7.4) at 70°C, the scattering blended for 15seconds with a high shear homogenizer and speedily a brief time frame later "rose" at 70°C using nitrogen.

APPLICATIONS OF NIOSOMES:

Niosomal drug delivery for their action against various diseases is potentially applicable to many pharmacological agents. A few of its treatment applications are as follows:

Targeting Of Bioactive Agents

1. To Reticulo-Endothelial System (RES)

Preferentially the vesicles occupy RES cells. It is known as opsonins due to circulating serum factors, which mark them for clearance. Be that as it may, such restricted aggregation of medications has been taken advantage of in the treatment of creature cancers known to metastasize the liver and spleen and in a parasitic hepatic invasion.

2. To Organs Other Than Reticulo-Endothelial System (RES)

The carrier mechanism can be guided to specific sites in the body by the use of antibodies. Immunoglobulins tend to have lipid surface affection and thus provide a convenient means of targeting the drug carrier. Many cells have the intrinsic ability to recognize and bind specific carbohydrate determinants and this property can be used to direct the carrier system to specific cells.

Neoplasia:

The anthracyclic antibiotic doxorubicin shows a dose-dependent irreversible cardio-toxic effect, with broad-spectrum anti-tumor activity. The drug's half-life is increased by its niosomal drug trapping, as well as prolonging its circulation and altering its metabolism. If the mice with S-180 tumors are treated with niosomal delivery of this drug, the lifespan of the mice increased and the incidence of sarcoma proliferation decreased.

Niosomal methotrexate when intravenously administered to S-180 tumor-bearing mice results in complete tumor regression, higher plasma rates, and slower removal.

Immunological Applications Of Niosomes:

Niosomes have been utilized to concentrate on the embodiment of the resistant reaction brought about by antigens. In terms of immunological selectivity, low toxicity, and stability, niosomes have been identified as potent adjuvants.

Niosome as a Carrier For Hemoglobin:

Niosomal suspension has a noticeable range that can be superimposed on free hemoglobin to be utilized as a hemoglobin transporter. Vesicles are likewise oxygen-penetrable and the bend of hemoglobin-separation can be changed much the same way to non-typified hemoglobin.

Transdermal Delivery Of Drugs By Niosomes:

Transdermal medication conveyance coordinated in niosomes has accomplished an improvement in infiltration rate, as languid medication entrance through the skin is the significant disadvantage of transdermal conveyance course for other measurements structures. The effective conveyance of erythromycin from various plans like niosomes has been tried on smooth mice and tests, moreover, confocal microscopy has seen that non-ionic vesicles can be planned to target pilosebaceous organs.

OTHER APPLICATIONS:

1. Sustained Release:

By niosomal encapsulation, drugs with low therapeutic index and higher water solubility may be retained in circulation, and continuous release action can be achieved by niosomes. The suggested function of the liver as a methotrexate depot after the liver cells take up niosomes.

2. Localized Drug Action:

Niosomal dosage form is one of the approaches to achieving localized drug action due to the size of niosomes and their low penetrability via epithelium and connective tissue, the drug located at the site of administration. It increases the drug's efficacy and potency, and also decreases its systemic toxic effects, e.g. Mononuclear cells devour antimonials embodied inside niosomes, bringing about item restriction, expanded intensity, and subsequently diminished in both portion and poisonousness.

CHARACTERIZATION OF NIOSOMES:

Niosomes are regularly assessed during the detailing system and capacity as per their size, drug stacking proficiency, surface morphology, and soundness. Such qualities are vital for niosomes as they influence not just the embodiment rate and the steadiness of the niosomes, yet additionally their in vivo effectiveness.

Microscopy:

Nuclear power microscopy (AFM), examining electron microscopy (SEM), and transmission electron microscopy (TEM) methods are utilized to evaluate the morphology of the niosomes to all the more likely recognize the sharp niosomes. Niosomes are seldom self-gathered and require energy as the main impetus, for example, warming or mechanical stirring. It is feasible to utilize confocal laser checking microscopy (CLSM) to distinguish the distinction between niosomes and discomes. The measures of the niosomes were expressed to differ generally, from around 20 nm to 50 μ m. 35

Sizes and Zeta Potential:

A laser dissipating molecule size analyzer is utilized to decide the polydispersity list (PDI) and size dissemination. Dynamic light dissipating, zeta-sizer and microelectrophoresis are utilized to decide zeta potential, which is needed to look at the solidness of niosomes in the arrangement.

Encapsulation Efficiency:

The exemplification viability is the capacity of vesicles to stack restorative specialists. It centers generally around the sort of nonionic surfactant, the technique for amalgamation, and different specialists utilized during the time spent to plan, like cholesterol. It is assessed that the epitome rate could surpass 75% to around 90%, however, it is commonly inside the 10 to 40% territory.

Stability:

Niosomal security assumes a significant part in the advancement of its detailing. The strategy for arrangement, stacked medications, and assortments of layer shaping materials impact it. The varieties in molecule size, zeta potential, morphology, and stacked item spill hazard can be determined to decide the soundness for their bundling. To decide the wellbeing of

niosomes during flow, these medication-charged vesicles can be hatched at 37°C and in serum (or much under brutal conditions) to repeat in vivo conditions.

Bilayer Formation:

Bilayer vesicle arrangement because of the get together of non-ionic surfactants under light polarization microscopy can be portrayed by x-cross development.

Number of Lamellae:

Little point X-beam dispersing, NMR spectroscopy, and electron microscopy are utilized to portray the quantity of lamella in vesicles.

In-vitro Drug Release:

Drug delivery might be constrained by dialyzing niosomal suspension against the cradle at a specific temperature and by surveying the item content of dialysate.

CONCLUSION:

Right now, center around vesicular medication conveyance frameworks like liposomes and niosomes have been drawn in. Niosome is unmistakably a favored medication conveyance framework over liposomes. Niosomes offer a compelling, delayed, helpful, and designated drug conveyance framework with both hydrophilic and lipophilic medication stacking capacities. Niosome capacity can be worked on using new strategies for creation, stacking, and change. Such regions, along these lines, require further examination and study, to create promoted niosomal arrangements.

REFERENCES:

1. Sharma A, Kumar L, Kumar P, Prasad N, Rastogi V. Niosomes: a promising approach in drug delivery systems. *Journal of Drug Delivery and Therapeutics*. 2019
2. Saraswathi TS, Mothilal M, Jaga Nathan MK. Niosomes as an emerging formulation tool for drug delivery—a review. *International Journal of Applied Pharmaceutics*. 2019
3. Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular systems: an overview. *Indian Journal of Pharmaceutical Sciences*. 2006
4. Ray SK, Bano N, Shukla T, Upmanyu N, Pandey SP, Parkhe G. Niosomes: as novel vesicular drug delivery system. *Journal of Drug Delivery and Therapeutics*. 2018
5. Devi SG, Udupa N. Niosomal sumatriptan succinate for nasal administration. *Indian Journal of Pharmaceutical Sciences*. 2000
6. Khandare JN., Madhavi G., Tamhankar BM., Niosomes Novel Drug Delivery System. *The Eastern Pharmacist*. 1994.
7. Baillie AJ., Florence AT., Hume LR., Muirhead GT., Rogerson A., The preparation and properties of niosomes non-ionic surfactant vesicles. 1985

8. Handjani-Vila RM, Dispersion of Lamellar Phases of Nonionic Lipids In Cosmetic Products, Int J Cosmetic Sci, 1979
9. <http://en.wikipedia.org/wiki/Niosomes>, the structure of niosomes.
10. Rogerson A., Cummings J., Willmott N., Florence AT., The distribution of doxorubicin in mice following administration in niosomes. 1980
11. M Nvs; A Saini. Int J Res Pharm Chem. 2011
12. C Hu; DG Rhodes. Int J Pharm.1999,
13. G Parthasarathi; N Udupa; GK Pillai. 1994
14. <http://en.wikipedia.org/wiki/Niosomes>, Structure of Niosomes.
15. RR Naresh; GK Pillai; N Udupa; G Chandrashekar.1994
16. Khandare JN., Madhavi G., Tamhankar BM., Niosomes Novel Drug Delivery System. 1994
17. Baillie AJ., Florence AT., Hume LR., Muirhead GT., Rogerson A., The preparation and properties of niosomes non-ionic surfactant vesicles. 1985
18. <http://en.wikipedia.org/wiki/Niosomes>, the structure of niosomes.
19. Rogerson A., Cummings J., Willmott N., Florence AT., The distribution of doxorubicin in mice following administration in niosomes. 1988
20. Biju SS., Talegaonkar S., Misra PR., Khar RK., Vesicular systems: An overview. Indian J. Pharm. 2006

